Beta Thalassemia Treatments
Find Beta Thalassemia Treatments
Generic Name
Mitapivat
Brand Names
Pyrukynd, Aqvesme
FDA approval date: February 18, 2022
Classification: Pyruvate Kinase Activator
Form: Tablet, Kit
What is Pyrukynd (Mitapivat)?
PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies - Canada (SATISFY-CA)
Summary: This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will ...